Amgen’s Mvasi Set For Blockbuster Status With 50% Share In US
Annualized Biosimilars Sales Tracking North Of $2bn On Bevacizumab Boom
Amgen’s biosimilars sales will almost certainly smash through the $2bn barrier in 2021, driven by the strength of its product portfolio including bevacizumab and trastuzumab. The California-based biotech has warned, however, that greater competition will naturally lead to pricing challenges.
